🇺🇸 Pneumococcal conjugate Vaccine in United States

87 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 15 reports (17.24%)
  2. Cough — 11 reports (12.64%)
  3. Dyspnoea — 11 reports (12.64%)
  4. Gastrooesophageal Reflux Disease — 8 reports (9.2%)
  5. Abdominal Pain — 7 reports (8.05%)
  6. Diarrhoea — 7 reports (8.05%)
  7. Fatigue — 7 reports (8.05%)
  8. Hypersensitivity — 7 reports (8.05%)
  9. Nausea — 7 reports (8.05%)
  10. Pain — 7 reports (8.05%)

Source database →

Pneumococcal conjugate Vaccine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Pneumococcal conjugate Vaccine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Pneumococcal conjugate Vaccine in United States?

Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.